Investor Presentation

Mgmt Guided Margin ImprovementCfo Debt Reduction RoadmapPromoter Disclosed Acquisition PlansOrder Pipeline DisclosedInvestor Communications View source PDF

VIYASH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+8.6%1-day move

₹228.00

prior close

₹233.88

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+1.2+1.1+3.0+14.5+8.6+8.0+14.8+12.9+9.6+9.5+9.3+18.8+16.0—

Up moveDown movePending

AI summary

Viyash Scientific reported its strongest quarter ever in Q4 FY26, with revenues of ₹9,200 million (up 19.1% YoY) and EBITDA of ₹2,001 million (up 63.8% YoY). Full-year FY26 revenues stood at ₹34,203 million with EBITDA of ₹7,025 million, both showing robust growth. The company completed its merger integration, which has started reflecting in improved operating leverage and financial performance. EBITDA margins expanded by 590 basis points YoY to 21.7% in Q4. The balance sheet has been significantly deleveraged with net debt reduced from ₹4,511 million to ₹1,661 million, resulting in a Net Debt/EBITDA ratio of just 0.2x. Revenue mix shows Formulations (₹18,657 million) and APIs (₹14,906 million) as key segments, with strong growth across Europe (+19%), Emerging Markets (+23%), and India (+22%).

Likely market impact

The strong Q4 performance and merger synergy realization indicate improving operational efficiency and execution capability. The significantly deleveraged balance sheet provides financial flexibility for future growth. The company is actively evaluating inorganic opportunities, which could accelerate expansion.